Publication details
Nová – přímá perorální antikoagulancia: aktuální přehled
| Title in English | New – direct oral anticoagulants: actual review |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Vnitřní lékařství |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | apixaban; dabigatran; DOAC; NOAC; rivaroxaban |
| Description | In recent years the options of anticoagulant/antithrombotic therapy have extended with new – direct oral anticoagulants, comprising direct thrombin inhibitors (dabigatran etexilate) and direct factor Xa inhibitors (rivaroxaban, apixaban). These agents represent another progress towards “the ideal antithrombotic drug“, and thus towards a safe and effective antithrombotic therapy. The following article provides actual review and recommendations for clinical practice, including laboratory assessment and management of emergency situations. The approval of idarucizumab as a specific antidote for dabigatran has marked an important step in safety of this treatment. |
| Related projects: |